- Inhibitors
- Antibodies
- Compound Libraries
- New Products
- Contact Us
research use only
Cat.No.S3843
|
In vitro |
DMSO
: 100 mg/mL
(102.55 mM)
Water : 100 mg/mL Ethanol : 100 mg/mL |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 975.12 | Formula | C48H78O20 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 34540-22-2 | -- | Storage of Stock Solutions |
|
|
| In vitro |
Madecassoside (10, 30, 100 μmol/L) could reverse morphological changes, elevate cell viability, increase glutathione levels, and decrease lactate dehydrogenase and malondialdehyde levels caused by H₂O₂ in a concentration-dependent manner. It attenuates apoptosis, preventing the activation of caspase-3 and the loss of mitochondria membrane potential, as well as the phosphorylation of p38 mitogen activated protein kinase (MAPK) in HUVECs. Hence, this compound could protect HUVECs against lipid peroxidation and apoptosis caused by H₂O₂.
|
|---|---|
| In vivo |
The pharmacokinetic study of madecassoside in rats indicates that the maximum plasma concentration is 303.75 ± 28.53 ng/mL after single oral administration (100 mg/kg). This compound, administered orally for 20 days at doses of 6, 12, and 24 mg/kg, effectively facilitates burn wound healing in mice. It could reduce the burn wound area, leading to a better healing pattern with almost complete wound closure in mice. This chemical has potent anti-pulmonary fibrosis (PF) effects when administered p.o., despite having extremely low oral bioavailability. The potent anti-PF effects induced by p.o. this compound in mice are not mediated by its metabolites or itself after absorption into blood. i.p. this chemical has no anti-PF effect. It increases the activity of PPAR-γ, which subsequently increases HGF expression in colonic epithelial cells. HGF then enters into the circulation and lung tissue to exert an anti-PF effect.
|
References |
|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT02353273 | Completed | Diabetic Foot |
Oneness Biotech Co. Ltd. |
July 22 2015 | Phase 1 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.